THRB and breast cancer: Since high VEGF-C and VEGF-D levels lead to a poor prognosis in breast cancer, our finding that NCoR and TRβ are potent inhibitors of these factors suggests that they may serve as novel therapeutic targets to inhibit lymphangiogenesis and breast tumor progression.